As the world emerges from the COVID-19 pandemic, healthcare fraud enforcement remains a top priority for the US Department of Justice (DOJ) and other government agencies with enforcement authority. In this Westlaw Today article, McDermott Partners Laura McLane, Tony Maida and Dana M. McSherry describe some of the areas that have assumed particularly high enforcement priority, including private equity, telehealth and pandemic relief funds.
Healthcare Enforcement in the Post-Pandemic Era
Laura McLaneLaura McLane heads the Boston Litigation Practice Group and is a nationally renowned False Claims Act (FCA) litigator in healthcare and life sciences enforcement matters. For more than 20 years, Laura has represented clients in healthcare, securities and other government investigations and litigation. Clients call Laura “an exquisite lawyer, very smart and incisive” (Chambers USA). Read Laura McLane's full bio.
Tony MaidaTony Maida counsels health care and life sciences clients on government investigations, regulatory compliance and compliance program development. Having served as a government official, Tony has extensive experience in health care fraud and abuse and compliance issues, including the federal and state Anti-Kickback and Stark Laws and Medicare and Medicaid coverage and payment rules. He represents clients in False Claims Act (FCA) qui tam matters, government audits, civil monetary penalty and exclusion investigations, and Centers for Medicare and Medicaid Services (CMS) suspension, and revocation actions, negotiating and implementing corporate integrity agreements, and making government self-disclosures. Read Tony Maida's full bio.
Dana McSherryDana McSherry advises healthcare and life sciences companies in criminal and civil government enforcement matters and in related civil litigation, including civil False Claims Act litigation. She advises clients concerning all aspects of civil and criminal investigations relating to Medicare and Medicaid billing and other government contracting issues, including negotiating with the government and managing clients’ responses to civil investigative demands and large-scale investigative subpoenas. Dana also assists clients in conducting internal investigations and counsels clients across the healthcare industry on compliance and risk management issues.Read Dana M. McSherry's full bio.
Related Posts
BLOG EDITORS
STAY CONNECTED
TOPICS
ARCHIVES
RECENT POSTS
- Complying With the ‘Relevant Data’ Requirement Under the Final 2024 Mental Health Parity and Addiction Equity Act: A Proposal for a Workable Alternative
- HHS Letter Reiterates Expectations for Language Accessibility
- Employee Benefit Plans: Important Considerations for Year-End and 2025
- Post-Election Outlook: Issues to Watch for Pharmacy Industry Stakeholders
- Post-Election Health Policy Priorities
